Search Results
10
Everything
Serina Therapeutics Reports Full Year 2024 Financial Results and Recent Business Highlights
March 24, 2025 16:30 ET
|
Serina Therapeutics, Inc.
HUNTSVILLE, March 24, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug...
Clearmind to Evaluate Intranasal Delivery of Its Psychedelic Drug Combination
March 19, 2025 07:35 ET
|
Clearmind Medicine Inc.
Aiming to improve bioavailability and optimize the therapeutic effect of Clearmind’s psychedelic-based treatments Vancouver, Canada, March 19, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc....
Palisade Bio Commences Dosing in First Ulcerative Colitis Patient Cohort in Ongoing Phase 1a/b Study of PALI-2108
March 14, 2025 08:30 ET
|
Palisade Bio, Inc.
Positive preliminary data from all five single ascending dose (SAD) cohorts and first three completed multiple ascending dose (MAD) cohorts support safety and tolerability of PALI-2108 No serious...
Palisade Bio, Inc. Announces Receipt of Cash Proceeds from Canada’s SR&ED Tax Incentive Program for Reimbursement of Development Costs of PALI-2108 for Treatment of Ulcerative Colitis (UC)
February 20, 2025 08:45 ET
|
Palisade Bio, Inc.
Company through its co-development partner, Giiant Pharma, Inc. (“Giiant”), receives funding from Canadian Scientific Research and Experimental Development (SR&ED) Tax Credit Program for PALI-2108...
IMUNON to Hold 2024 Financial Results and Business Update Conference Call on Thursday, February 27, 2025
February 20, 2025 08:30 ET
|
Imunon, Inc.
LAWRENCEVILLE, N.J., Feb. 20, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, announces that the Company...
Palisade Bio Presents Positive Preclinical Data of PALI-2108 for the Treatment of Ulcerative Colitis
February 10, 2025 08:45 ET
|
Palisade Bio, Inc.
Data presented at the 2025 Crohn’s and Colitis Congress PALI-2108 demonstrated to effectively reduce colitis symptoms in DSS mouse model without CNS toxicity associated with systemic exposure ...
Greenwich LifeSciences Provides Update on Open Label HLA Data from FLAMINGO-01
February 10, 2025 06:00 ET
|
Greenwich LifeSciences, Inc.
STAFFORD, Texas, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial,...
Jupiter Neurosciences Addresses Market Volatility as it Remains Focused on Advancing Clinical and Commercial Milestones
February 04, 2025 09:25 ET
|
Jupiter Neurosciences, Inc.
Jupiter, Florida, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“Jupiter” or the “Company”), a clinical-stage pharmaceutical company developing JOTROL™, a patented...
Processa Pharmaceuticals Announces Closing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules
January 30, 2025 17:17 ET
|
Processa Pharmaceuticals, Inc.
HANOVER, Md, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next...
Palisade Bio Selected for Poster Presentation at the 2025 Crohn’s & Colitis Congress
January 29, 2025 08:45 ET
|
Palisade Bio, Inc.
Carlsbad, CA, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a clinical-stage biopharmaceutical company focused on...